// AST – IMS - [DMinute_ROS]

Phillips 66 (PSX) Holding Has Increased by Lau Associates Llc; Gilead Sciences (GILD) Stake Boosted by Meiji Yasuda Life Insurance Company

Gilead Sciences, Inc. (NASDAQ:GILD) Logo

Meiji Yasuda Life Insurance Company increased its stake in Gilead Sciences Inc (GILD) by 30.4% based on its latest 2018Q3 regulatory filing with the SEC. Meiji Yasuda Life Insurance Company bought 9,250 shares as the company’s stock declined 6.92% with the market. The institutional investor held 39,678 shares of the health care company at the end of 2018Q3, valued at $3.06M, up from 30,428 at the end of the previous reported quarter. Meiji Yasuda Life Insurance Company who had been investing in Gilead Sciences Inc for a number of months, seems to be bullish on the $88.17 billion market cap company. The stock increased 0.18% or $0.12 during the last trading session, reaching $68.16. About 5.66 million shares traded. Gilead Sciences, Inc. (NASDAQ:GILD) has declined 7.19% since January 12, 2018 and is downtrending. It has underperformed by 7.19% the S&P500. Some Historical GILD News: 31/05/2018 – ACR20 80 — not too shabby: Gilead and Galapagos bag promising PhII data for star immunology drug filgotinib – boosting late-stage focus $GILD $GLPG; 23/04/2018 – Gilead Bond Trading 2x Average; Clients Net Sellers; 26/04/2018 – CAFC: GILEAD SCIENCES, INC. v. MERCK & CO., INC. [ERRATA] – Appeal #16-2302 – 2018-04-26; 21/05/2018 – Janssen Announces European Commission Approval of JULUCA®▼ (dolutegravir/rilpivirine), the First Two-Drug Regimen, Once-Daily, Single-Pill for the Treatment of HIV-1; 30/04/2018 – Gilead and Verily Announce Scientific Collaboration to Identify and Understand Immunological and Molecular Drivers of; 15/05/2018 – GILEAD: FDA APPROVED TRUVADA IN ADOLESCENTS; 15/05/2018 – U.S. Food and Drug Administration Approves Expanded Indication for Truvada® (Emtricitabine and Tenofovir Disoproxil Fumarate); 30/05/2018 – REG-GILEAD AND GALAPAGOS ANNOUNCE RESULTS WITH FILGOTINIB IN THE PHASE 2 EQUATOR STUDY IN PSORIATIC ARTHRITIS AND PROGRESSION INTO PHASE 3 FOR THE SELECTION STUDY IN ULCERATIVE COLITIS; 21/05/2018 – ViiV Healthcare Will Market Dolutegravir/rilpivirine in All Countries in the European Union and European Economic Area; 23/04/2018 – Gilead’s Descovy Falls After 2-Wk Rise, Triumeq Declines: HIV

Lau Associates Llc increased its stake in Phillips 66 Inc (PSX) by 17.06% based on its latest 2018Q3 regulatory filing with the SEC. Lau Associates Llc bought 6,300 shares as the company’s stock declined 22.04% with the market. The institutional investor held 43,220 shares of the integrated oil company at the end of 2018Q3, valued at $4.87M, up from 36,920 at the end of the previous reported quarter. Lau Associates Llc who had been investing in Phillips 66 Inc for a number of months, seems to be bullish on the $42.74 billion market cap company. The stock decreased 0.27% or $0.25 during the last trading session, reaching $92.69. About 2.10 million shares traded. Phillips 66 (NYSE:PSX) has declined 9.22% since January 12, 2018 and is downtrending. It has underperformed by 9.22% the S&P500. Some Historical PSX News: 17/04/2018 – Phillips 66’s JV Borger, Texas gasoline units due back next week; 09/04/2018 – Phillips 66 JV Borger refinery continuing to restart units; 12/04/2018 – PHILLIPS 66 BORGER REFINERY EXPECTS ALL UNITS TO BE BACK IN PRODUCTION BY MIDDLE OF NEXT WEEK; 27/04/2018 – PHILLIPS 66 PSX.N SAYS NEEDS NEW PIPELINE CAPACITY SERVING THE PERMIAN BASIN – CONF CALL; 27/04/2018 – PHILLIPS 66 – EARNINGS REFLECT BENEFIT OF DIVERSIFIED PORTFOLIO, AND ARE ALSO SEEING POSITIVE, ONGOING IMPACTS FROM U.S. TAX REFORM; 09/05/2018 – PHILLIPS 66 PSX.N INCREASES QUARTERLY DIVIDEND BY 14 PCT TO $0.80/SHR; 16/04/2018 – Phillips 66 restarting JV Borger, Texas refinery gasoline units; 03/04/2018 – PHILLIPS 66 ALLIANCE REFINERY COMPLETES HYDROTREATER RESTART; 11/04/2018 – PHILLIPS 66 JV BORGER TEXAS REFINERY SHUTS GASOLINE UNITS, HYDROTREATER; 06/04/2018 – PHILLIPS 66 JV BORGER TEXAS REFINERY RETURNING ALL UNITS TO PRODUCTION

Since November 20, 2018, it had 1 buying transaction, and 0 sales for $1.98 million activity.

More important recent Phillips 66 (NYSE:PSX) news were published by: Seekingalpha.com which released: “Phillips 66: Reloading The Growth Pipeline In 2019 – Seeking Alpha” on December 16, 2018, also Seekingalpha.com published article titled: “Nurdles are no laughing matter, as oil companies asked to disclose problem – Seeking Alpha”, Seekingalpha.com published: “Phillips 66 – My Opinion After The Third Quarter 2018 – Seeking Alpha” on December 14, 2018. More interesting news about Phillips 66 (NYSE:PSX) was released by: Investorplace.com and their article: “5 Oil Stocks to Buy Even If Oil Prices Keep Falling – Investorplace.com” with publication date: December 19, 2018.

Among 22 analysts covering Phillips 66 (NYSE:PSX), 13 have Buy rating, 0 Sell and 9 Hold. Therefore 59% are positive. Phillips 66 had 97 analyst reports since August 4, 2015 according to SRatingsIntel. As per Monday, April 30, the company rating was maintained by Barclays Capital. On Wednesday, January 24 the stock rating was maintained by Citigroup with “Neutral”. Credit Suisse downgraded the shares of PSX in report on Monday, November 2 to “Neutral” rating. The stock of Phillips 66 (NYSE:PSX) has “Sell” rating given on Wednesday, January 24 by Jefferies. The firm has “Outperform” rating given on Monday, October 29 by Raymond James. As per Wednesday, October 3, the company rating was upgraded by Barclays Capital. The firm earned “Sector Perform” rating on Monday, July 11 by Howard Weil. As per Thursday, May 25, the company rating was maintained by PiperJaffray. The rating was maintained by Piper Jaffray with “Buy” on Monday, April 23. As per Monday, February 6, the company rating was maintained by Mizuho.

Investors sentiment increased to 1.19 in Q3 2018. Its up 0.03, from 1.16 in 2018Q2. It is positive, as 35 investors sold PSX shares while 356 reduced holdings. 113 funds opened positions while 351 raised stakes. 305.42 million shares or 2.74% less from 314.02 million shares in 2018Q2 were reported. Pinebridge Investments LP has invested 0.42% in Phillips 66 (NYSE:PSX). Denali Advsrs Ltd Liability Co holds 56,200 shares. Payden & Rygel stated it has 224,160 shares or 1.93% of all its holdings. Wagner Bowman Mgmt Corp has 0.17% invested in Phillips 66 (NYSE:PSX) for 6,095 shares. Syntal Capital Partners Lc has invested 0.13% in Phillips 66 (NYSE:PSX). Thrivent For Lutherans invested 0.09% of its portfolio in Phillips 66 (NYSE:PSX). Leisure Cap holds 0.78% or 8,550 shares. Ubs Oconnor Limited Liability Corporation holds 0% or 35,000 shares in its portfolio. Quantres Asset Mngmt Ltd invested 0.5% of its portfolio in Phillips 66 (NYSE:PSX). 6,045 were reported by Segment Wealth Mgmt Ltd Llc. Willingdon Wealth Mngmt holds 0.04% or 1,232 shares. Bankshares Of America Corp De has invested 0.08% in Phillips 66 (NYSE:PSX). Mackay Shields Ltd Liability has 202,616 shares for 0.17% of their portfolio. Dubuque Commercial Bank & Tru holds 0.02% or 1,238 shares. Westwood Grp reported 9,282 shares.

Meiji Yasuda Life Insurance Company, which manages about $799.56M US Long portfolio, decreased its stake in Cintas Corp (NASDAQ:CTAS) by 6,570 shares to 11,000 shares, valued at $2.18M in 2018Q3, according to the filing. It also reduced its holding in Mcdonalds Corp (NYSE:MCD) by 3,511 shares in the quarter, leaving it with 13,779 shares, and cut its stake in Devon Energy Corp New (NYSE:DVN).

Since September 4, 2018, it had 0 insider purchases, and 4 sales for $14.65 million activity.

Investors sentiment increased to 0.89 in 2018 Q3. Its up 0.14, from 0.75 in 2018Q2. It is positive, as 43 investors sold GILD shares while 500 reduced holdings. 108 funds opened positions while 374 raised stakes. 963.01 million shares or 1.52% less from 977.84 million shares in 2018Q2 were reported. Orbimed Advsrs Ltd holds 364,600 shares. Meridian Invest Counsel Inc stated it has 1.3% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD). Nelson Roberts Invest Advsrs Limited Liability Co reported 79,859 shares. Healthcor Management Limited Partnership stated it has 132,870 shares. Hilton Capital Management Llc has invested 0.01% in Gilead Sciences, Inc. (NASDAQ:GILD). Excalibur Mgmt reported 0.88% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD). Zeke Cap Advsrs Ltd Liability Company reported 18,001 shares. Wheatland Inc holds 1.92% or 33,125 shares in its portfolio. Hennessy Advisors stated it has 0.2% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD). Sun Life Finance has 0.05% invested in Gilead Sciences, Inc. (NASDAQ:GILD). Tower Rech Capital Lc (Trc) has invested 0.02% in Gilead Sciences, Inc. (NASDAQ:GILD). 777 are held by Tci Wealth Advsr Inc. Moreover, Tdam Usa has 0.14% invested in Gilead Sciences, Inc. (NASDAQ:GILD) for 30,154 shares. Livforsakringsbolaget Skandia Omsesidigt, Sweden-based fund reported 78,237 shares. Gsa Llp has invested 0.1% in Gilead Sciences, Inc. (NASDAQ:GILD).

Among 33 analysts covering Gilead Sciences (NASDAQ:GILD), 23 have Buy rating, 0 Sell and 10 Hold. Therefore 70% are positive. Gilead Sciences had 141 analyst reports since July 29, 2015 according to SRatingsIntel. On Monday, November 13 the stock rating was downgraded by Argus Research to “Hold”. William Blair maintained the shares of GILD in report on Wednesday, June 14 with “Buy” rating. Leerink Swann downgraded the shares of GILD in report on Tuesday, September 27 to “Mkt Perform” rating. PiperJaffray downgraded Gilead Sciences, Inc. (NASDAQ:GILD) on Friday, October 26 to “Neutral” rating. RBC Capital Markets maintained the stock with “Buy” rating in Wednesday, February 7 report. The stock of Gilead Sciences, Inc. (NASDAQ:GILD) has “Neutral” rating given on Wednesday, February 8 by Citigroup. The firm earned “Hold” rating on Monday, August 28 by BMO Capital Markets. The stock has “Buy” rating by Jefferies on Tuesday, September 6. The company was maintained on Thursday, July 26 by Morgan Stanley. The stock has “Hold” rating by Oppenheimer on Wednesday, October 4.

More notable recent Gilead Sciences, Inc. (NASDAQ:GILD) news were published by: Nasdaq.com which released: “AGEN Soars On GILD Deal, FENC Rolling Ahead, AIMT Gaining Steam – Nasdaq” on December 20, 2018, also Seekingalpha.com with their article: “Gilead teams up with Precision BioSciences in HBV – Seeking Alpha” published on September 12, 2018, Nasdaq.com published: “GILD Makes Notable Cross Below Critical Moving Average – Nasdaq” on August 15, 2018. More interesting news about Gilead Sciences, Inc. (NASDAQ:GILD) were released by: Nasdaq.com and their article: “Should Value Investors Consider Gilead (GILD) Stock Now? – Nasdaq” published on November 21, 2018 as well as Nasdaq.com‘s news article titled: “Alexion’s Ultomiris Gets Early FDA Nod for Rare Blood Disorder – Nasdaq” with publication date: December 24, 2018.

Gilead Sciences, Inc. (NASDAQ:GILD) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.